DXCM SEC Filings

DexCom, Inc. (DXCM) has filed an 8-K report on July 30, 2026, to disclose its financial results for the second quarter ended June 30, 2026. The primary purpose of this filing is to furnish a press release announcing these results, which provides investors with key performance indicators and financial condition updates. While this information is furnished and not deemed 'filed' for liability purposes under Section 18 of the Exchange Act, it represents the company's official communication regarding its recent performance. Investors should refer to the press release (Exhibit 99.1) for specific details on revenue, profitability, and any forward-looking statements or guidance provided by DexCom for the upcoming periods. The filing indicates that further details beyond the summary provided in the 8-K's Item 2.02 will be found within this attached press release, which is crucial for a comprehensive understanding of the company's current financial standing and future outlook.

DexCom, Inc. (DXCM) reported strong financial performance for the second quarter and first half of 2026, demonstrating significant revenue and profit growth. The company's continuous glucose monitoring (CGM) systems continue to drive this expansion, with notable increases in customer base and revenue per customer. Management highlighted improved manufacturing efficiencies and favorable product mix as contributing factors to expanding gross margins. Financially, Dexcom maintained a robust liquidity position, with substantial cash, cash equivalents, and marketable securities. The company also initiated a significant share repurchase program in the second quarter of 2026, signaling confidence in its financial health and commitment to returning value to shareholders. While facing ongoing litigation, the company asserts it is defending vigorously and does not believe any currently pending proceedings will have a material adverse effect on its business.

DexCom, Inc. (DXCM) held its 2026 Annual Meeting of Stockholders on May 27, 2026, where key corporate governance and operational matters were presented to shareholders for a vote. The meeting saw strong participation, with a quorum established by the presence of 336,525,352 shares, representing over 87% of the outstanding common stock as of the April 1, 2026 record date. The primary outcomes of the meeting include the re-election of all twelve nominated directors to the board, each for a term extending to the 2027 annual meeting. Furthermore, stockholders overwhelmingly ratified the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The compensation of the company's named executive officers was also approved on an advisory, non-binding basis.

DEXCOM INC. (DXCM) filed an 8-K on May 15, 2026, detailing key strategic and financial announcements made during their 2026 Investor Day. The company presented ambitious long-range financial targets through 2030, emphasizing sustained organic revenue growth and significant improvements in profitability margins. These targets signal strong confidence in Dexcom's market position and future performance, which will be closely watched by investors. In addition to outlining its growth trajectory, Dexcom's Board of Directors approved a substantial $1.0 billion share repurchase program, signaling a commitment to returning capital to shareholders and potentially enhancing shareholder value. This strategic move, coupled with the long-term financial outlook, provides investors with a comprehensive view of Dexcom's forward-looking strategy, focusing on both growth initiatives and capital allocation.

DexCom, Inc. (DXCM) has filed an 8-K report on April 30, 2026, to announce its financial results for the first quarter ended March 31, 2026. While the filing itself is brief, it references a press release (Exhibit 99.1) containing the detailed financial and operational performance for the period. Investors should refer to this press release for crucial information regarding revenue, profitability, and any forward-looking guidance provided by the company. This filing serves as a notification mechanism for material updates. The company's performance in Q1 2026, as detailed in the press release, will be a key indicator for assessing its current trajectory and future prospects. Investors are advised to examine the press release for specific metrics and commentary that could influence their investment decisions, paying close attention to any management commentary on market trends, product adoption, and competitive landscape.

DexCom, Inc. (DXCM) reported a strong first quarter for 2026, demonstrating significant top-line growth and substantial improvements in profitability. Revenue increased by 15% year-over-year to $1.19 billion, driven by increased sales volume of their continuous glucose monitoring (CGM) systems. This revenue growth, coupled with improved manufacturing efficiencies and a favorable product mix, led to a notable expansion in gross profit margin to 62.9% and a substantial 91% increase in operating income. The company also achieved robust net income growth of 89% to $199.5 million, translating to a diluted EPS of $0.51. The balance sheet remains strong, with cash, cash equivalents, and short-term marketable securities totaling $2.42 billion, providing ample liquidity. Operating cash flow saw a significant increase of 186% to $525.6 million, underscoring the company's operational efficiency and cash generation capabilities. Despite ongoing legal proceedings, DexCom appears to be navigating these challenges while continuing to invest in its core business and expand its market reach.

This 8-K filing from DexCom, Inc. (DXCM) on March 2, 2026, primarily reports on the return of Kevin R. Sayer to his role as Executive Chairman of the Board, effective March 2, 2026, after a temporary leave of absence. Mr. Sayer's transition from CEO to Executive Chairman was previously announced, and his return signifies a continuation of his leadership and strategic guidance for the company. This filing also details the new compensation arrangement for his role as Executive Chairman.

DexCom, Inc. (DXCM) announced a strategic expansion of its Board of Directors, increasing its size to twelve members with the immediate appointment of Albert F. (“Rick”) Osterloh, IV. Mr. Osterloh's appointment is effective as of February 26, 2026, and he will serve until the 2026 annual meeting of stockholders. His addition is expected to bring valuable experience to the company, as he has been appointed to key committees, including the Compensation Committee and the Technology Committee, underscoring his role in governance and strategic oversight. This move appears to be a proactive step in strengthening DexCom's leadership structure. Mr. Osterloh's independence has been confirmed, and his compensation aligns with the company's non-employee director program, including an initial equity grant of $500,000 in restricted stock units vesting over three years, and a pro-rated annual equity grant for his service. Investors should monitor how Mr. Osterloh's expertise influences the company's strategic decisions, particularly in technology and compensation, moving forward.

DexCom, Inc. (DXCM) has filed an 8-K report on February 12, 2026, to announce its financial results for the fourth quarter and full year ended December 31, 2025. The primary purpose of this filing is to furnish the accompanying press release, which contains key financial and operational updates for investors. Investors should refer to the press release (Exhibit 99.1) for the detailed financial performance, strategic initiatives, and forward-looking statements made by the company. While the specific financial figures are not detailed within the 8-K text itself, this report signals the company's official communication of its year-end and quarterly performance. The furnishing of this information means it is provided for informational purposes and is not deemed "filed" under the Securities Exchange Act of 1934, thus not subject to specific liability sections of that act. Investors are advised to carefully review the press release for comprehensive details on revenue, profitability, product development, and any guidance for the upcoming fiscal year.

DexCom, Inc. (DXCM) reported a strong fiscal year 2025, with revenue reaching $4.66 billion, a 16% increase year-over-year. This growth was primarily driven by increased sales volume of their continuous glucose monitoring (CGM) systems, particularly the Dexcom G7 and the recently launched G7 15 Day system. The company added approximately 600,000-700,000 net customers in 2025. Despite increased sales, gross profit margin saw a slight decrease due to supply availability inefficiencies and build configuration impacts. However, operating income grew significantly by 52%, reaching $911.8 million, supported by controlled operating expenses and a substantial increase in other income. Net income also saw robust growth, up 45% to $836.3 million. The company ended the year with a strong liquidity position, holding $2.00 billion in cash, cash equivalents, and marketable securities, demonstrating effective financial management amidst product innovation and market expansion. The company continues to focus on product development and market expansion, with the recent launch of the Stelo biosensor for prediabetes and Type 2 diabetes patients who do not use insulin marking a strategic move to broaden their market reach. Dexcom is also actively managing regulatory landscapes, addressing an FDA warning letter received in March 2025 regarding manufacturing process non-conformities, and has submitted responses. The company is well-positioned for continued growth, driven by its innovative product pipeline and expanding global presence, though it faces ongoing competitive pressures and evolving reimbursement policies.

This 8-K filing from DexCom, Inc. (DXCM) serves as a notification regarding upcoming presentations and releases of preliminary financial results. President and CEO Jake Leach is scheduled to present at the J.P. Morgan 44th Annual Healthcare Conference on January 12, 2026, where he will share unaudited financial results for the fourth quarter and full fiscal year 2025, along with initial financial outlook for fiscal year 2026. Investors should note that these results are preliminary and subject to finalization in the upcoming Form 10-K. The filing also references a business update press release issued on January 7, 2026, and includes these materials as exhibits. It's crucial for investors to understand that forward-looking statements within these releases are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.

DexCom, Inc. (DXCM) has filed an 8-K report detailing the official appointment of Jacob S. Leach as President and Chief Executive Officer, effective January 1, 2026. This transition follows Mr. Leach's service as interim principal executive officer during Kevin R. Sayer's medical leave. The filing outlines the key terms of Mr. Leach's new role, including an annual base salary of $1,150,000 and a target bonus opportunity of 150% of his base salary. Furthermore, Mr. Leach will receive significant equity awards, comprising restricted stock units valued at $7,500,000 and performance stock units with a target value of $7,500,000, both vesting over several years and contingent on continued service and performance conditions. This leadership change represents a pivotal moment for DexCom as it moves forward under new permanent executive leadership. Investors will be keen to observe Mr. Leach's strategic direction and execution in his permanent CEO role, especially considering the substantial incentive package designed to align his interests with long-term shareholder value. The report also confirms that Kevin R. Sayer is expected to return from his medical leave around March 2026, with Mark Foletta continuing as interim Chairman of the Board until then.

DexCom, Inc. (DXCM) has filed an 8-K report on October 30, 2025, to announce its financial results for the quarter ended September 30, 2025. This filing primarily serves to furnish a press release detailing these results and other pertinent information. Investors should note that the information provided in this Item 2.02 and its exhibit is furnished and not deemed "filed" for regulatory purposes, meaning it does not carry the same liabilities as a formally filed document under Section 18 of the Exchange Act. The press release, furnished as Exhibit 99.1, contains DexCom's operational and financial performance for the third quarter of 2025. While the specifics of the financial results are within the attached press release, this 8-K filing itself is the mechanism through which the market is being officially informed of these key performance indicators. Investors are encouraged to review Exhibit 99.1 for detailed financial metrics and commentary.

DexCom, Inc. (DXCM) reported a strong third quarter for 2025, demonstrating significant year-over-year growth across key financial metrics. Revenue increased by 22% to $1.21 billion, driven by a robust expansion of their customer base and continued demand for their continuous glucose monitoring (CGM) systems. This top-line growth translated into substantial improvements in profitability, with gross profit up 23% and operating income soaring by 60%. Net income more than doubled, increasing by 111% to $283.8 million, indicating enhanced operational efficiency and effective cost management. The company's financial position remains solid, with a significant increase in cash, cash equivalents, and short-term marketable securities to $3.32 billion. This robust liquidity provides DexCom with ample resources to fund ongoing operations, capital expenditures, and strategic initiatives, including ongoing product development and potential expansion into new markets. The successful launch of the Stelo biosensor and the FDA clearance for the Dexcom G7 15 Day CGM System further bolster the company's product portfolio and market reach. Despite ongoing legal proceedings and regulatory scrutiny, Dexcom has demonstrated impressive financial performance and a positive outlook for continued growth.

DexCom, Inc. (DXCM) announced a change in its Board of Directors composition through an 8-K filing on October 27, 2025. The company has appointed Dr. Euan Ashley as a new director, effective immediately, increasing the Board's size to ten members. Dr. Ashley's appointment is significant as he brings expertise and will serve on the Nominating and Governance Committee and the Technology Committee. This move is part of a broader board expansion strategy previously announced, which includes the appointment of Jacob S. Leach effective January 1, 2026. The appointment of Dr. Ashley is structured with a standard director compensation package, including an initial equity grant of $500,000 in restricted stock units (RSUs) vesting over three years, and eligibility for future annual equity awards. His qualifications are deemed independent, aligning with Nasdaq listing standards. This strategic addition to the board aims to bolster governance and technological oversight, reflecting DexCom's commitment to strong leadership as it continues to grow.

DexCom, Inc. (DXCM) has announced that its Chief Executive Officer and Chairman of the Board, Kevin R. Sayer, is taking a temporary medical leave of absence, effective September 14, 2025. This development necessitates a temporary leadership transition to ensure continuity of operations and strategic direction. In response, the Board of Directors has appointed Jacob S. Leach, currently President and Chief Operating Officer, to serve as the interim principal executive officer. Additionally, Mark Foletta, the Lead Independent Director, has been appointed as the interim Chairman of the Board. Investors should note that neither Mr. Leach nor Mr. Foletta will receive additional compensation for these interim roles, signaling a commitment to stable governance during this period. The company has emphasized that Mr. Leach's appointment is not subject to any specific arrangements or understandings with other parties and that he has no material interests in any reportable transactions.

DexCom, Inc. (DXCM) has filed an 8-K report detailing its financial results for the quarter ended June 30, 2025, and announcing significant leadership transitions. While specific financial figures are not provided in this extract, the company has confirmed the release of its quarterly earnings through a press release furnished as Exhibit 99.1. Investors should refer to this press release for detailed performance metrics and operational highlights for the period. The most substantial news in this filing pertains to executive leadership. CEO Kevin R. Sayer will retire from his CEO role effective January 1, 2026, transitioning to Executive Chairman. Concurrently, current President and COO, Jacob S. Leach, will assume the CEO position on January 1, 2026. Mr. Leach will also join the Board of Directors as part of these changes. The company stated that no new compensatory arrangements have been finalized for these roles as of the filing date.

DexCom, Inc. (DXCM) reported its second-quarter results for the period ending June 30, 2025, demonstrating continued revenue growth and improved profitability. For the three months ended June 30, 2025, the company generated $1.16 billion in revenue, a 15% increase year-over-year, driven by robust sales volume of its disposable sensors and a growing global customer base. Gross profit saw a 10% increase to $688.8 million, though the gross profit margin slightly decreased due to inefficiencies in supply availability, build configurations, and product mix. Operating income significantly improved by 35% to $212.6 million, reflecting strong revenue growth coupled with a decrease in selling, general, and administrative expenses, partly due to lower legal costs. Net income for the quarter rose by 25% to $179.8 million, resulting in diluted earnings per share of $0.45. The company maintained a strong liquidity position, ending the quarter with $2.93 billion in cash, cash equivalents, and short-term marketable securities. Management is focused on product innovation, global expansion, and strategic partnerships, while also navigating regulatory considerations, including an FDA warning letter received in March 2025.

DexCom, Inc. (DXCM) has announced a significant leadership change with the promotion of Jacob S. Leach to President and Chief Operating Officer, effective immediately. This appointment places Mr. Leach directly under CEO Kevin Sayer and signifies a strengthening of the operational leadership team. Investors should note that Mr. Leach's compensation has been adjusted to reflect his new role, including a base salary of $800,000 and eligibility for a performance-based annual cash bonus targeted at 100% of his base salary. This promotion is a key development for DexCom as it continues to execute its growth strategy in the diabetes technology market. The elevated role for Mr. Leach, who has been with the company, suggests confidence in his ability to drive operational execution and strategic initiatives. The associated compensation structure is designed to incentivize strong performance and align executive interests with those of shareholders.

DexCom, Inc. (DXCM) has filed an amendment to its prior 8-K filing, specifically addressing the committee appointments for newly appointed board member Ms. Renée Galá. Initially appointed to the board on March 6, 2025, the company is now confirming her service on two key committees: the Audit Committee and the Compensation Committee. These appointments are effective immediately as of May 9, 2025.

DexCom, Inc. (DXCM) filed an 8-K on May 9, 2025, detailing the outcomes of its Annual Meeting of Stockholders held on May 8, 2025. The primary focus for investors is the stockholder approval of significant amendments to the company's equity and employee stock purchase plans. Specifically, the Amended and Restated 2015 Equity Incentive Plan (A&R 2015 EIP) was approved, increasing the share reserve by 3.4 million shares, and the Amended and Restated 2015 Employee Stock Purchase Plan (A&R 2015 ESPP) was also approved, adding 8 million shares to its reserve. These approvals are crucial for DexCom's ability to continue attracting and retaining talent through stock-based compensation and employee ownership programs, supporting future growth and operational expansion. In addition to compensation-related plans, stockholders also elected nine directors to the board, ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2025, and provided advisory approval for named executive officer compensation. A notable governance change was the board's decision to decrease its size to nine directors, effective May 8, 2025. The substantial 'Votes For' on all proposals indicate strong shareholder support for management's proposed actions and compensation strategies.

DexCom, Inc. (DXCM) announced in an 8-K filing dated May 2, 2025, that director Karen Dahut will be resigning from the Board of Directors and all associated committees, effective May 8, 2025. The company has explicitly stated that Ms. Dahut's departure is not due to any disagreements with the company, its management, or its board, nor is it related to any issues concerning the company's operations, policies, or practices. This communication signals a routine board transition rather than a cause for concern regarding internal discord or operational challenges.

DexCom, Inc. (DXCM) announced its first quarter 2025 financial results and a significant new share repurchase program in an 8-K filing dated May 1, 2025. While the press release containing the detailed financial results is furnished as an exhibit and not deemed 'filed' for liability purposes, the announcement of these results is a key event for investors. The company also revealed a new authorization for a share repurchase program valued at up to $750.0 million of its outstanding common stock, with a repurchase period extending through June 30, 2026. This dual announcement provides investors with an update on DexCom's recent performance and a clear signal of management's confidence in the company's value, demonstrated by the substantial capital allocation towards share buybacks. The flexibility in repurchase methods, including Rule 10b5-1 trading plans, allows DexCom to execute the program efficiently while navigating market conditions. Investors will be keen to examine the specific financial metrics released in the accompanying press release to understand the drivers behind these results and the ongoing strategic direction of the company.

DexCom, Inc. (DXCM) reported its first quarter 2025 financial results, showcasing continued revenue growth driven by increased sensor sales volume and a growing global customer base. While revenue saw a healthy 12% year-over-year increase to $1.04 billion, the company experienced a notable decrease in net income to $105.4 million from $146.4 million in the prior year. This decline was primarily attributed to a significant increase in income tax expense, partly due to shortfalls in share-based compensation, and increased cost of sales which compressed gross profit margins. The company ended the quarter with a strong liquidity position, holding $2.70 billion in cash, cash equivalents, and marketable securities. Management highlighted strategic investments in R&D and product development, including the recent FDA clearance of the Dexcom G7 15 Day CGM System and the launch of the Stelo biosensor for prediabetes and Type 2 diabetes. Despite operational efficiencies in selling, general, and administrative expenses, driven by lower legal costs, investors should monitor the impact of increased cost of goods sold and rising tax expenses on future profitability.

DexCom, Inc. (DXCM) has announced a change in its independent registered public accounting firm. The Audit Committee of the Board of Directors, on March 21, 2025, dismissed Ernst & Young LLP (EY) as the Company's auditor. This change is effective for the fiscal years ended December 31, 2024 and 2023, and the subsequent interim period. The company states that there were no disagreements or reportable events with EY during these periods, and EY has confirmed its agreement with this statement. This transition is a routine procedural event, but investors should be aware of the change in auditor. Concurrently, DexCom has engaged Deloitte & Touche LLP (Deloitte) as its new independent registered public accounting firm for the fiscal year ending December 31, 2025. The company has confirmed that there were no consultations with Deloitte on accounting principles, disagreements, or reportable events prior to this engagement. The engagement of a new auditor is a common occurrence and typically does not indicate any underlying issues with the company's financial reporting, but it does mark a significant change in the oversight of DexCom's financial statements.

DexCom, Inc. (DXCM) announced a key governance update on March 10, 2025, via an 8-K filing. The company has expanded its Board of Directors to eleven members with the immediate appointment of Renée Galá. Ms. Galá's appointment is effective through the 2025 annual meeting of stockholders and she has been deemed an independent director, aligning with Nasdaq listing standards. This expansion and appointment suggest a proactive approach by DexCom to strengthen its board's expertise and oversight. Investors should note that Ms. Galá's compensation includes an initial equity grant of $500,000 in Restricted Stock Units (RSUs) vesting over three years, and a pro-rated annual equity grant of approximately $56,986. This compensation structure is typical for non-employee directors and aligns their interests with long-term shareholder value through equity ownership.

DexCom, Inc. (DXCM) disclosed on March 7, 2025, that it received a warning letter from the U.S. Food and Drug Administration (FDA) on March 4, 2025, following inspections of its San Diego and Mesa facilities. The FDA cited deficiencies related to manufacturing processes and quality management systems, stemming from earlier Form 483 observations. Importantly, the company stated that this warning letter does not restrict its ability to produce, market, manufacture, or distribute products, nor does it necessitate a recall or prevent the pursuit of 510(k) clearance for new products. Despite the seriousness of the FDA's concerns, DexCom asserted that it does not expect a material impact on its manufacturing capacity or its previously issued fiscal year 2025 revenue guidance. The company is actively preparing a response to the warning letter and has already submitted responses to the Form 483. While DexCom is committed to corrective actions and updates to the FDA, it cannot guarantee the FDA's satisfaction with its response or provide an estimated timeline for resolution, acknowledging that further regulatory action remains a possibility.

DexCom, Inc. (DXCM) has demonstrated robust performance in its latest annual report, driven by strong growth in its continuous glucose monitoring (CGM) systems. The company reported significant revenue growth, primarily fueled by increased sales volumes of its disposable sensors, indicating a growing global customer base. This expansion was supported by the launch of its Stelo biosensor in August 2024, targeting the prediabetes and Type 2 diabetes non-insulin user market, marking an entry into the over-the-counter space. Despite increased cost of sales due to higher volume and freight costs, the company managed to grow its gross profit, though gross profit margin saw a slight decrease. Overall, Dexcom maintained operating income and saw a notable increase in operating cash flow, reflecting effective operational management and continued demand for its innovative diabetes management solutions.

DexCom, Inc. (DXCM) filed an 8-K on February 13, 2025, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2024. The press release containing these results, furnished as Exhibit 99.1, is the main focus of this filing. Investors should refer to this press release for detailed financial performance, operational updates, and any forward-looking statements regarding the company's outlook. This filing serves as the official notification of these key financial outcomes. While the 8-K itself is brief, the accompanying press release is crucial for understanding DexCom's performance in the period. Investors will be looking for information on revenue growth, profitability metrics, any significant changes in guidance, and commentary on market trends impacting the continuous glucose monitoring (CGM) sector. The furnished information is not considered "filed" for liability purposes under Section 18 of the Exchange Act, but it is the primary source for the reported financial and operational data.

DexCom, Inc. (DXCM) has filed a Form 8-K to provide preliminary, unaudited financial results for the fourth quarter and full fiscal year 2024, along with initial financial guidance for fiscal year 2025. These updates were shared during a presentation at the J.P. Morgan 43rd Annual Healthcare Conference on January 13, 2025, by CEO Kevin Sayer. Investors should note that these results are preliminary and subject to finalization during the preparation of the upcoming Form 10-K. The filing also contains forward-looking statements regarding revenue, gross profit margin, and operating margin, which are subject to inherent risks and uncertainties that could cause actual results to differ materially.

DexCom, Inc. (DXCM) has announced the resolution of its ongoing global patent litigation with Abbott Diabetes Care, Inc. (Abbott). The parties entered into a comprehensive settlement and patent cross-license agreement on December 20, 2024, which effectively terminates all outstanding legal disputes concerning patent infringements and invalidation claims. This agreement is highly positive for DexCom as it eliminates significant legal costs and uncertainty associated with the protracted litigation. The terms include a royalty-free, non-exclusive, and fully paid-up license for both companies to use certain patents related to analyte sensing, including those previously contested. Furthermore, a mutual covenant not to sue is established until December 20, 2034, providing a decade of peace from further patent challenges from Abbott. This resolution allows DexCom to focus its resources and strategic efforts entirely on its business operations and innovation without the overhang of this litigation.

DexCom, Inc. (DXCM) has filed an 8-K report on October 24, 2024, primarily to announce its financial results for the quarter ended September 30, 2024, via a press release furnished as Exhibit 99.1. While the specific financial figures are not detailed within the 8-K text itself, this filing serves as the official notification channel for investors and the market regarding the company's most recent performance. Investors should refer to the press release (Exhibit 99.1) for comprehensive details on revenue, profitability, and any forward-looking guidance provided by the company. This filing is crucial for understanding DexCom's operational and financial standing as of the third quarter of 2024. This report is furnished, not filed, meaning it does not carry the same legal liabilities as a fully filed document under Section 18 of the Exchange Act. However, it remains the primary source for timely information dissemination regarding DexCom's financial results. Investors and analysts will be closely examining the information within the accompanying press release to assess the company's growth trajectory, competitive position, and overall financial health within the diabetes technology market.

DexCom, Inc. (DXCM) reported its financial results for the quarter and nine months ended September 30, 2024. Revenue for the third quarter increased by 2% year-over-year to $994.2 million, and by 13% for the nine-month period to $2,919.5 million. While revenue showed growth, gross profit saw a slight decrease of 5% in the third quarter to $593.8 million, attributed to product and channel mix changes and a non-cash inventory charge. Net income for the third quarter increased by 12% to $134.6 million, resulting in diluted EPS of $0.34. For the nine-month period, net income surged by 49% to $424.5 million, with diluted EPS at $1.04. The company ended the period with a strong liquidity position, including $2.49 billion in cash, cash equivalents, and short-term marketable securities. Operating cash flow for the nine months was robust at $688.1 million. Significant strategic initiatives include the launch of Stelo, a new biosensor for adults with prediabetes and Type 2 diabetes, and continued investment in R&D and international expansion. However, investors should note ongoing patent litigation with Abbott and recent securities class action lawsuits, which introduce considerable uncertainty.

DexCom, Inc. (DXCM) has filed an 8-K report on July 25, 2024, announcing two significant developments for investors. Firstly, the company issued a press release detailing its financial results for the quarter ended June 30, 2024. While the specifics of these results are not included directly in the 8-K text, their release indicates a regular update on operational performance. Investors should refer to the furnished press release (Exhibit 99.1) for detailed financial metrics, revenue figures, and profitability. Secondly, DexCom's Board of Directors has authorized a substantial share repurchase program valued at up to $750.0 million, with repurchases expected to conclude by June 30, 2025. This program signals management's confidence in the company's intrinsic value and its commitment to returning capital to shareholders. The repurchases can be executed through various market mechanisms, including 10b5-1 plans, at the company's discretion, depending on market conditions.

DexCom, Inc. reported a strong second quarter for 2024, demonstrating robust growth and profitability. Revenue increased by 15% year-over-year to $1.004 billion, driven by sustained demand for their continuous glucose monitoring (CGM) systems. Gross profit also grew by 15% to $626.7 million, indicating effective cost management alongside sales expansion. The company achieved significant operating income growth of 23%, reaching $158.0 million, and net income surged by 24% to $143.5 million, highlighting operational efficiency and strong earnings power. The company's balance sheet remains healthy, with cash, cash equivalents, and short-term marketable securities totaling $3.12 billion, providing substantial liquidity. Cash flow from operations was particularly strong, showing a 47% increase year-over-year for the quarter, underscoring the company's ability to generate substantial cash from its core business activities. Furthermore, DexCom announced a new $750 million share repurchase program, signaling confidence in its financial position and commitment to returning value to shareholders.

This 8-K filing from DexCom, Inc. (DXCM) reports the outcomes of its 2024 Annual Meeting of Stockholders held on May 22, 2024. The meeting resulted in the overwhelming election of all ten director nominees, underscoring strong board support from shareholders. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, a crucial vote of confidence in the company's financial oversight. Furthermore, the advisory vote to approve the compensation of named executive officers passed, indicating general shareholder satisfaction with executive pay structures. However, the filing also details the outcomes of two stockholder proposals, with one concerning pay equity disclosure failing to gain majority support, while a proposal for transparency in lobbying was approved. These results provide insight into shareholder sentiment on corporate governance and executive compensation.

DexCom, Inc. reported strong financial performance for the first quarter of 2024, with revenue increasing by 24% year-over-year to $921.0 million. This growth was primarily driven by an increase in sales volume of their continuous glucose monitoring (CGM) systems, adding approximately 600,000 users to their global customer base in the prior year. The company also demonstrated significant profitability improvements, with operating income soaring by 114% and net income more than tripling to $146.4 million, resulting in a diluted EPS of $0.36. Operationally, DexCom continues to invest in research and development to enhance its product offerings and expand into new markets, including individuals with Type 2 diabetes not using insulin. The company's balance sheet remains robust, with cash, cash equivalents, and marketable securities totaling $2.90 billion at the end of the quarter, and positive operating cash flow of $209.2 million underscores its financial strength. However, investors should note ongoing patent litigation with Abbott, which, while currently assessed as not likely to result in a material adverse outcome, remains a point of ongoing legal scrutiny.

DexCom, Inc. (DXCM) has filed an 8-K report on April 25, 2024, to announce its financial results for the first quarter ended March 31, 2024. The report primarily directs investors to a furnished press release (Exhibit 99.1) for detailed financial performance and operational updates. Investors should note that the information provided in this Item 2.02 and Exhibit 99.1 is furnished, not filed, meaning it is not subject to the same liability provisions as a formally filed document under Section 18 of the Exchange Act and is not automatically incorporated into other DexCom filings unless specifically referenced. This disclosure style is common for earnings releases, with the full details of the quarter's performance contained within the accompanying press release.

DexCom, Inc. (DXCM) has entered into a Warrant Termination Agreement with Bank of America, N.A. (BofA) on February 13, 2024, to terminate outstanding warrants related to its 0.75% Convertible Senior Notes due 2023. These warrants were originally issued in connection with the convertible notes and associated hedge and warrant transactions with BofA and JPMorgan Chase Bank (JPM). The termination agreement will resolve approximately 10.3 million shares of common stock warrants held by BofA. In exchange for the warrant termination, DexCom will issue shares of its common stock to BofA. The number of shares will be determined by the daily volume-weighted average price of DexCom's common stock over a specified averaging period expected to conclude in the first quarter of 2024. This transaction is being conducted under an exemption from registration, implying it is not being offered to the public and is intended to simplify the company's capital structure and remove potential future dilution from these specific warrants.

DexCom, Inc. (DXCM) reported strong revenue growth of 24% year-over-year, reaching $3.62 billion for the fiscal year ended December 31, 2023. This growth was primarily driven by increased sales volumes of their disposable continuous glucose monitoring (CGM) sensors, reflecting continued expansion of their global customer base. The company achieved significant improvements in profitability, with operating income up 53% and net income up 59% compared to the previous year. Dexcom's latest generation products, the G6 and G7 CGM systems, continue to drive adoption. The G7, launched in late 2022, offers key improvements such as a smaller profile, faster warm-up time, and enhanced features, further solidifying Dexcom's position in the diabetes management market. The company also noted ongoing progress in expanding its manufacturing capabilities and is actively pursuing strategic partnerships to broaden market access and enhance product offerings. Despite facing ongoing patent litigation with Abbott and various market risks, Dexcom's financial performance and strategic initiatives indicate a strong outlook for continued growth in the diabetes technology sector.

DexCom, Inc. (DXCM) has filed an 8-K report on February 8, 2024, to announce its financial results for the fourth quarter and full year ended December 31, 2023. The filing primarily consists of a press release (Exhibit 99.1) detailing these results and other relevant information. Investors should note that the information furnished in this Item 2.02 is not considered "filed" for legal liability purposes under Section 18 of the Exchange Act, nor is it automatically incorporated into future SEC filings unless specifically referenced. While the 8-K itself does not contain the detailed financial figures, it directs investors to the accompanying press release for the complete financial performance. This includes key metrics for both the recent quarter and the full fiscal year, providing a comprehensive update on the company's operational and financial condition. Investors are encouraged to review Exhibit 99.1 for the specific revenue, profit, and any forward-looking guidance provided by DexCom.

DexCom, Inc. (DXCM) has filed an 8-K report on January 8, 2024, providing preliminary, unaudited financial results for the fourth quarter and full fiscal year 2023, along with an initial financial outlook for 2024. The company anticipates strong revenue growth, with Q4 2023 revenue expected to reach at least $1.030 billion, a 26% increase year-over-year. For the full fiscal year 2023, total revenue is projected to be around $3.62 billion, marking a 24% increase from 2022. Looking ahead to fiscal year 2024, DexCom has provided an initial revenue outlook, forecasting a total revenue range of approximately $4.15 billion to $4.35 billion. This guidance suggests continued growth for the company in the upcoming year, driven by its diabetes monitoring technologies. Investors should note that these results are preliminary and unaudited, subject to finalization in DexCom's upcoming Form 10-K filing.

DexCom, Inc. (DXCM) announced on November 2, 2023, through an 8-K filing, its entry into an accelerated share repurchase (ASR) agreement with Bank of America, N.A. for up to $500.0 million. This strategic move signals management's confidence in the company's intrinsic value and its commitment to returning capital to shareholders. The company has already made an initial payment of $500.0 million and received approximately 4.7 million shares, effective October 31, 2023. This ASR transaction is part of DexCom's previously authorized $500.0 million share repurchase program and is expected to be finalized within the fourth quarter of 2023. The ultimate number of shares repurchased will be determined by the daily volume-weighted average price, less a discount, with potential for additional shares or a cash settlement. This action suggests the company believes its shares are currently undervalued, aiming to enhance shareholder value by reducing the outstanding share count.

DexCom Inc. (DXCM) reported strong financial performance for the third quarter and first nine months of 2023, demonstrating significant revenue and profit growth year-over-year. The company's revenue increased by 27% in the third quarter and 24% for the nine-month period, driven by robust sales volume of its continuous glucose monitoring (CGM) systems, particularly with the ongoing adoption of the G7 system. Gross profit also saw healthy increases, up 26% for the quarter and 22% year-to-date, indicating effective cost management alongside sales growth. Financially, DexCom maintains a solid liquidity position with over $3.2 billion in cash, cash equivalents, and short-term marketable securities as of September 30, 2023. The company generated substantial positive cash flow from operations, underscoring its operational efficiency. Management remains focused on strategic investments in research and development and manufacturing capabilities to support future growth, including international expansion. Despite ongoing patent litigation with Abbott and various market risks, the company's operational and financial performance indicates a positive trajectory.

DexCom, Inc. (DXCM) filed an 8-K on October 26, 2023, to announce its financial results for the third quarter ended September 30, 2023. The filing includes a press release detailing the company's performance and other relevant information. While this 8-K is primarily an informational filing and the contents are furnished rather than deemed 'filed' for regulatory purposes, it provides investors with timely updates on the company's operational and financial standing. Investors should refer to the furnished press release for specific details on the quarterly performance, as it contains the primary financial disclosures. This report is crucial for understanding DexCom's recent business trajectory and financial health as it relates to the third quarter of 2023. It serves as a direct communication channel from the company to its shareholders regarding its financial results and operational highlights. Investors seeking a comprehensive understanding of DexCom's performance should carefully review the accompanying press release, which is incorporated by reference into this filing.

Dexcom, Inc. (DXCM) announced on October 24, 2023, that its Board of Directors has approved a significant share repurchase program valued at up to $500 million of its outstanding common stock. This program, set to conclude by October 31, 2024, signals management's confidence in the company's intrinsic value and its commitment to enhancing shareholder returns. The buyback will be executed opportunistically through various methods, including open market transactions and privately negotiated deals, adhering to regulatory guidelines.

DexCom, Inc. (DXCM) announced the appointment of Rimma Driscoll to its Board of Directors, effective August 24, 2023. Ms. Driscoll will fill a vacant seat and will also serve on the Audit Committee and the Technology Committee. Her appointment strengthens the board's expertise and governance structure, particularly in areas critical to DexCom's business operations and innovation. She is considered an independent director under Nasdaq listing standards. In connection with her appointment, Ms. Driscoll will receive equity compensation, including an initial retainer grant of restricted stock units (RSUs) valued at $500,000, vesting over three years, and a customary annual RSU grant valued at $325,000, vesting in one year. This compensation aligns with the company's policy for non-employee directors and is intended to incentivize long-term value creation. The company also announced this appointment via a press release, which is furnished as an exhibit to this filing.

DexCom, Inc. reported a strong second quarter of 2023, demonstrating robust financial performance with significant year-over-year growth in revenue and profitability. The company saw revenue increase by 25% to $871.3 million, driven by higher sales volumes of its disposable sensors, reflecting continued global customer base expansion. Profitability also showed substantial improvement, with operating income up 66% and net income more than doubling to $115.9 million. This was supported by a gross profit increase of 22% and effective management of operating expenses, despite higher SG&A costs primarily due to increased headcount and marketing initiatives. The company ended the quarter with a healthy cash position of $3.64 billion, indicating strong financial health and ample resources for future growth initiatives. Looking ahead, DexCom anticipates continued growth driven by the increasing incidence of diabetes, demand for digital health technologies, and expansion into new markets and patient populations. However, investors should remain aware of ongoing patent litigation with Abbott and potential pricing pressures from third-party payors. The company's strategic investments in manufacturing capacity, particularly in Malaysia and Ireland, are expected to support future demand.

DexCom, Inc. (DXCM) filed an 8-K on July 27, 2023, primarily to announce its financial results for the second quarter ended June 30, 2023. While the 8-K itself doesn't contain the detailed financial figures, it references a furnished press release (Exhibit 99.1) that provides these operational and financial updates. Investors should refer to this press release for specific revenue, profit, and other key performance indicators for the quarter. The filing also includes standard legal disclaimers, noting that the information furnished is not considered "filed" for certain regulatory purposes, meaning it doesn't automatically incorporate into other SEC filings unless specifically referenced. This is a routine disclosure practice for companies announcing earnings via press release.

DexCom, Inc. (DXCM) filed an 8-K on June 26, 2023, primarily to disclose information presented at their Investor Day on June 23, 2023. The key takeaway for investors is an update to the company's long-range financial targets. While the specific updated targets are detailed in the furnished press release (Exhibit 99.1), this filing indicates a forward-looking strategic communication from DexCom regarding its growth trajectory and financial outlook. Investors should review the associated press release and Investor Day presentation, which are referenced in the filing and available on DexCom's investor relations website, for comprehensive details on these updated financial goals. This information is crucial for understanding management's expectations for future performance and assessing the company's long-term value proposition. It's important to note that the information furnished under Item 7.01 is not considered "filed" and therefore does not carry the same regulatory implications as formally filed information.